Complete enrollment in both DPN Phase 3 studies of suzetrigine
Deadline not yet reached (65 days left)
- Announced
- 4 Aug 2025
- Due
- 31 Dec 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Vertex expects to complete enrollment in both DPN Phase 3 studies by the end of next year.”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 4 Aug 2025
Deadline 31 Dec 2026 (“by the end of next year”) · wording expected
-
Version 2 · stated 3 Aug 2026
Deadline 31 Dec 2026 (“by the end of 2026”) · wording firm
“Vertex is on track to complete enrollment in both Phase 3 studies of suzetrigine in diabetic peripheral neuropathy (DPN)... by the end of 2026.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Enrollment in both DPN Phase 3 studies of suzetrigine
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-VRTX-006550 · Corrections policy